The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / August / From Training Burden to Training Value 
Business & Regulation Development & Clinical Regulation & Standards Business & Trends Technology & Manufacturing Sponsored

From Training Burden to Training Value 

Why effective study training depends on relevance, timing, and oversight.

08/14/2026 0 min read Interview

Share

Study training is essential to clinical trial compliance, but assigning, tracking, and documenting it across global studies can consume time better spent improving training quality and impact. Reducing that burden helps ensure that each person receives the right training at the right time.

Tine De Pla of Amgen and Aidan Gannon of Veeva Systems discuss how role-based automation can strengthen oversight, reduce unnecessary training, and deliver more timely, useful learning. They also explore the links between effective training, patient safety, trial execution, and data quality.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings From the Power List: Jason Bock
Development & Clinical Cell & Gene Interviews
Musings From the Power List: Jason Bock

October 14, 2026

12 min read

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith
Development & Clinical Biopharma Interviews
Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

October 12, 2026

8 min read

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

The Staying Power of Small Molecules
Development & Clinical Small Molecules Business & Trends
The Staying Power of Small Molecules

October 8, 2026

4 min read

We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins

Musings from The Power List: Andres Sirulnik
Development & Clinical Biopharma Interviews
Musings from The Power List: Andres Sirulnik

October 5, 2026

4 min read

Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: